Benz S, Sherman KA, Dasanu CA, Alvarez-Argote J (2023) Immune checkpoint inhibitor-related adverse events: Real-world experience from a single veterans' affairs medical center. J Oncol Pharm Pract: 10781552231184178. https://doi.org/10.1177/10781552231184178

Weber JS, Kähler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30:2691–2697. https://doi.org/10.1200/jco.2012.41.6750

Article  CAS  PubMed  Google Scholar 

Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 26:1824–1829. https://doi.org/10.1093/annonc/mdv182

Article  CAS  PubMed  Google Scholar 

Rapoport BL, Anderson R, Cooksley T, Johnson DB (2020) MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. Support Care Cancer 28:6107–6110. https://doi.org/10.1007/s00520-020-05727-z

Article  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481

Article  CAS  PubMed  Google Scholar 

Usui Y, Miura T, Kawaguchi T, Kosugi K, Uehara Y, Kato M, Kosugi T, Sone M, Nakamura N, Mizushima A, Miyashita M, Morita T, Yamaguchi T, Matsumoto Y, Satomi E (2022) Palliative care physicians’ recognition of patients after immune checkpoint inhibitors and immune-related adverse events. Support Care Cancer 30:775–784. https://doi.org/10.1007/s00520-021-06482-5

Article  PubMed  Google Scholar 

El Majzoub I, Qdaisat A, Thein KZ, Win MA, Han MM, Jacobson K, Chaftari PS, Prejean M, Reyes-Gibby C, Yeung SJ (2019) Adverse effects of immune checkpoint therapy in cancer patients visiting the emergency department of a comprehensive cancer center. Ann Emerg Med 73:79–87. https://doi.org/10.1016/j.annemergmed.2018.04.019

Article  PubMed  Google Scholar 

(2017) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf Accessed 15 October 2024

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 335:806–808. https://doi.org/10.1136/bmj.39335.541782.AD

Article  Google Scholar 

Qin S, Xu L, Yi M, Yu S, Wu K, Luo S (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer 18:155. https://doi.org/10.1186/s12943-019-1091-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zubiri L, Molina GE, Mooradian MJ, Cohen J, Durbin SM, Petrillo L, Boland GM, Juric D, Dougan M, Thomas MF, Faje AT, Rengarajan M, Guidon AC, Chen ST, Okin D, Medoff BD, Nasrallah M, Kohler MJ, Schoenfeld SR, Karp-Leaf RS, Sise ME, Neilan TG, Zlotoff DA, Farmer JR, Bardia A, Sullivan RJ, Blum SM, Semenov YR, Villani AC, Reynolds KL (2021) Effect of a multidisciplinary severe immunotherapy complications service on outcomes for patients receiving immune checkpoint inhibitor therapy for cancer. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002886

Article  PubMed  PubMed Central  Google Scholar 

Koldenhof JJ, van der Baan FH, Verberne EG, Kamphuis AM, Verheijden RJ, Tonk EH, van Lindert AS, van der Stap J, Teunissen SC, Witteveen PO, Suijkerbuijk KP (2022) Patient-reported outcomes during checkpoint inhibition: insight into symptom burden in daily clinical practice. J Pain Symptom Manage 63:997–1005. https://doi.org/10.1016/j.jpainsymman.2022.02.013

Article  PubMed  Google Scholar 

Hansen ED, Wang X, Case AA, Puzanov I, Smith T (2018) Immune checkpoint inhibitor toxicity review for the palliative care clinician. J Pain Symptom Manage 56:460–472. https://doi.org/10.1016/j.jpainsymman.2018.05.015

Article  PubMed  Google Scholar 

Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377–2385. https://doi.org/10.1093/annonc/mdx286

Article  CAS  PubMed  Google Scholar 

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563–580. https://doi.org/10.1038/s41571-019-0218-0

Article  CAS  PubMed  Google Scholar 

Lawson DH (1994) Postmarketing surveillance versus clinical trials: which benefits the patient? Cardiology 85(Suppl 1):18–23

PubMed  Google Scholar 

Kim HS, Lee S, Kim JH (2018) Real-world evidence versus randomized controlled trial: clinical research based on electronic medical records. J Korean Med Sci 33:e213. https://doi.org/10.3346/jkms.2018.33.e213

Article  PubMed  PubMed Central  Google Scholar 

Templeton AJ, Vera-Badillo FE, Wang L, Attalla M, De Gouveia P, Leibowitz-Amit R, Knox JJ, Moore M, Sridhar SS, Joshua AM, Pond GR, Amir E, Tannock IF (2013) Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 24:2972–2977. https://doi.org/10.1093/annonc/mdt397

Article  CAS  PubMed  Google Scholar 

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073–4126. https://doi.org/10.1200/jco.21.01440

Article  CAS  PubMed  Google Scholar 

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, HolterChakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J Clin Oncol 36:1714–1768. https://doi.org/10.1200/jco.2017.77.6385

Article  CAS  PubMed  Google Scholar 

Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28: iv119-iv142. https://doi.org/10.1093/annonc/mdx225

Strunk A, Batzler YN, Ziemer M, Neukirchen M, Schwartz J, Sachse M, Garzarolli M, Strasser C, Reinhardt L, Kaatz M, Schuler U, Meier F (2023) Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases. Ann Palliat Med 12: 826–833. https://doi.org/10.21037/apm-22-1077

Miyashita M, Hirai K, Morita T, Sanjo M, Uchitomi Y (2008) Barriers to referral to inpatient palliative care units in Japan: a qualitative survey with content analysis. Support Care Cancer 16:217–222. https://doi.org/10.1007/s00520-007-0215-1

Article  PubMed  Google Scholar